The NK1 receptor antagonist NKP608 lacks anxiolytic-like activity in Swiss-Webster mice exposed to the elevated plus-maze

Behavioural Brain Research

Volumn 154, Issue 1, 2004, Pages 183-192

  Rodgers, R J ^a   Gentsch, C ^b   Hoyer, D ^b   Bryant, E ^a   Green, A J ^a   Kolokotroni, K Z ^a   Martin, J L ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Anxiety; Chlordiazepoxide; Mice; NK1 receptors; NKP608; Plus maze; Substance P; Tachykinins

Indexed keywords

BENZODIAZEPINE; CHLORDIAZEPOXIDE; NEUROKININ 1 RECEPTOR ANTAGONIST; NKP 608; QUINOLINE 4 CARBOXYLIC ACID [1 (3,5 BISTRIFLUOROMETHYLBENZOYL) 2 (4 CHLOROBENZYL)PIPERIDIN 4 YL]AMIDE; UNCLASSIFIED DRUG; ANXIOLYTIC AGENT; NEUROKININ 1 RECEPTOR; PIPERIDINE DERIVATIVE; QUINOLINE 4 CARBOXYLIC ACID (1 (3,5 BIS TRIFLUOROMETHYLBENZOYL) 2 (4 CHLOROBENZYL)PIPERIDIN 4 YL)AMIDE; QUINOLINE DERIVATIVE; QUINOLINE-4-CARBOXYLIC ACID (1-(3,5-BIS-TRIFLUOROMETHYLBENZOYL)-2-(4-CHLOROBENZYL)PIPERIDIN-4-YL)AMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; AVOIDANCE BEHAVIOR; BRAIN CORTEX; BRAIN TISSUE; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; EVALUATION; EXPOSURE; GERBIL; IC 50; IN VITRO STUDY; MALE; MAZE TEST; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; RAT; SAMPLING; SCORING SYSTEM; SOCIAL INTERACTION; STATISTICAL SIGNIFICANCE; TRANQUILIZING ACTIVITY; ANALYSIS OF VARIANCE; ANIMAL; BRAIN; COMPARATIVE STUDY; DRUG ANTAGONISM; METABOLISM; RANDOMIZATION;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-ANXIETY AGENTS; BRAIN; CEREBRAL CORTEX; CHLORDIAZEPOXIDE; CORPUS STRIATUM; DOSE-RESPONSE RELATIONSHIP, DRUG; GERBILLINAE; MAZE LEARNING; MICE; PIPERIDINES; QUINOLINES; RANDOM ALLOCATION; RATS; RECEPTORS, NEUROKININ-1;

EID: 4043162817     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2004.02.005     Document Type: Article

References (84)

1. Arai H., Emson P.C. Regional distribution of neuropeptide K and other tachykinins (neurokinin A, neurokinin B and substance P) in rat central nervous system. Brain Res. 399:1986;240-249
2. Ballenger J.C. Current treatments of the anxiety disorders in adults. Biol. Psychiat. 46:1999;1579-1594
3. Bannon M.J., Deutch A.Y., Tam S.Y., Zamir N., Eskay R.L., Lee J.M., et al. Mild footshock stress dissociates substance P from substance K and dynorphin from Met- and Leu-enkephalin. Brain Res. 381:1986;393-396
4. Baulmann J., Spitznagel H., Herdegen T., Unger T., Culman J. Effects of tachykinin receptor inhibition on stress-induced c-Fos expression in the rat brain. Neuroscience. 95:2000;813-820
5. Beresford I.J.M., Birch P.J., Hagan R.M., Ireland S.J. Investigation into species variants in tachykinin NK1 receptors by use of the non-peptide antagonist, CP-96,345. Br. J. Pharmacol. 104:1991;381-382
6. Blanco C., Antia S.X., Liebowitz M.R. Pharmacotherapy of social anxiety disorder. Biol. Psychiat. 51:2002;109-120
7. 1) receptor antagonists in rodent models of antidepressant and anxiolytic properties. Soc. Neurosci. Abstr. 28:2002;68313
8. Brodin E., Rosen A., Schott E., Brodin K. Effects of sequential removal of rats from a group cage and of individual housing of rats, on substance P, cholecystokinin and somatostatin levels in the periaqueductal grey and limbic regions. Neuropeptides. 26:1994;253-260
9. 4 receptors and anxiety: behavioural profiles of clozapine, L-745,870 and L-741,742 in the mouse plus-maze. Eur. J. Pharmacol. 335:1997;117-125
10. Carrasco G.A., Van de Kar L.D. Neuroendocrine pharmacology of stress. Eur. J. Pharmacol. 463:2003;235-272
11. 1A agonist 8-OH-DPAT in the social interaction test in gerbils. Brain Res. 915:2001;170-175
12. Cole J.C., Rodgers R.J. An ethological analysis of the effects of chlordiazepoxide and bretazenil (Ro 16-6028) in the murine elevated plus-maze. Behav. Pharmacol. 4:1993;573-580
13. Commons K., Valentino R. Cellular basis for the effects of substance P in the periaqueductal gray and dorsal raphe nucleus. J. Comp. Neurol. 447:2002;82-97
14. Crawley JN. What's wrong with my mouse? New York: Wiley-Liss; 2000. p. 329.
15. Culman J., Klee S., Ohlendorf C., Unger T. Effects of tachykinin receptor inhibition in the brain on cardiovascular and behavioral responses to stress. J. Pharmacol. Exp. Ther. 280:1997;238-246
16. Cutler MG. Potential anxiolytic activity in gerbils from the substance P receptor antagonist CGP49823. J Psychopharmacol 1994;A22.
17. Dam T.V., Escher E., Quirion R. Evidence for the existence of three classes of neurokinin receptors in brain. Differential ontogeny of neurokinin-1, neurokinin-2 and neurokinin-3 binding sites in rat cerebral cortex. Brain Res. 453:1988;372-376
18. De Araujo J.E., Silva R.C.B., Huston J.P., Brandao M.L. Anxiogenic effects of substance P and its 7-11 C terminal, but not the 1-7 N terminal, injected into the dorsal periaqueductal gray. Peptides. 20:1999;1437-1443
19. De Lima T.C.M., Ribeiro S.J. Central effects of tachykinin NK receptor agonists and antagonists on the elevated plus-maze behavior in rats. Soc. Neurosci. Abstr. 22:1996;1154
20. Elliott P.J., Iversen S.D. Behavioural effects of tachykinins and related peptides. Brain Res. 381:1986;68-76
21. Elliott P.J., Nemeroff C.B., Kilts C.D. Evidence for a tonic facilitatory influence of substance P on dopamine release in the nucleus accumbens. Brain Res. 386:1986;379-382
22. 1 receptor antagonist in the social interaction test. Pharmacol. Biochem. Behav. 58:1997;747-752
23. 1 receptor antagonist, has an anxiolytic action in the social interaction test in rats. Psychopharmacology. 152:2000;105-109
24. 1 receptor, and potent broad-spectrum anti-emetic activity. Regul. Peptides. 65:1996;45-53
25. Gavioli E.C., Canteras N.S., De Lima T.C.M. Anxiogenic-like effect induced by substance P injected into the lateral septal nucleus. NeuroReport. 10:1999;1-5
26. Gavioli E.C., Canteras N.S., De Lima T.C.M. The role of lateral septal NK1 receptors in mediating anxiogenic effects induced by intracerebroventricular injection of substance P. Behav. Brain Res. 134:2002;411-415
27. Gentsch C., Cutler M.G., Vassout A., Veenstra S., Brugger F. Anxiolytic effect of NKP608, a NK1-receptor antagonist, in the social investigation test in gerbils. Behav. Brain Res. 133:2002;363-368
28. Gentsch C, Vassout A, Veenstra S, Katz R, Brugger F. Preclinical profile of NKP608, a novel psychotropic acting at the NK-1 receptor. Paper Presented at the 38th Annual ACNP Meeting, Acapulco, Mexico; 1999.
29. Gerlai R. Gene targeting: technical confounds and potential solutions in behavioral brain research. Behav. Brain Res. 125:2001;13-21
30. Griebel G. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol. Ther. 82:1999;1-61
31. Griebel G., Moindrot N., Aliaga C., Simiand J., Soubrie P. Characterization of the profile of neurokinin-2 and neurotensin receptor antagonists in the mouse defense test battery. Neurosci. Biobehav. Rev. 25:2001;619-626
32. 2 receptor antagonist on emotional processes in rodents. Psychopharmacology. 158:2001;241-251
33. Handley S.L., Mithani S. Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of 'fear'-motivated behaviour. Naunyn-Schmideberg's Arch. Pharmacol. 327:1984;1-5
34. Hasenohrl R.U., De Souza-Silva M.A., Nikolaus S., Tomaz C., Brandao M.L., Schwarting R.K.W., et al. Substance P and its role in neural mechanisms governing learning, anxiety and functional recovery. Neuropeptides. 34:2000;272-280
35. Helke C.J., Krause J.E., Mantyh P.W., Couture R., Bannon M.J. Diversity in mammalian tachykinin peptidergic neurons: multiple peptides, receptors and regulatory mechanisms. FASEB J. 4:1990;1601-1615
36. Herpfer I., Lieb K. Substance P and substance P receptor antagonists in the pathogenesis and treatment of affective disorders. World J. Biol. Psychiat. 4:2003;56-63
37. Hogg S. A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol. Biochem. Behav. 54:1996;21-30
38. Holmes A., Rodgers R.J. Responses of Swiss-Webster mice to repeated plus-maze experience: further evidence for a qualitative shift in emotional state? Pharmacol. Biochem. Behav. 60:1998;473-488
39. Holmes A., Rodgers R.J. Prior exposure to the elevated plus-maze sensitizes mice to the acute behavioral effects of fluoxetine and phenelzine. Eur. J. Pharmacol. 459:2003;221-230
40. Holmes A., Iles J.P., Mayell S.J., Rodgers R.J. Prior test experience compromises the anxiolytic efficacy of chlordiazepoxide in the mouse light/dark exploration test. Behav. Brain Res. 122:2001;159-167
41. Kent JM, Mathew SJ, Gorman JM. Molecular targets in the treatment of anxiety. Biol Psychiat 52:1008-30.
42. Kramer M.S., Cutler N., Feighner J., Shrivastava R., Carman J., Sramek J.J., et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 281:1998;1640-1645
43. 3 antagonists and benzodiazepines: their comparative behavioural pharmacology. Chichester: Wiley; 1991. p. 343-63.
44. Landgraf R. Neuropeptides and anxiety-related behavior. Endocr. J. 48:2001;517-533
45. Lieb K., Treffurth Y., Berger M., Fiebich B.L. Susbtance P and affective disorders: new treatment opportunities by neurokinin 1 receptor antagonists? Neuropsychobiology. 45(Suppl):2002;2-6
46. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology. 92:1987;180-185
47. Maeno H., Kiyama H., Tohyama M. Distribution of the substance P receptor (NK-1 receptor) in the central nervous system. Mol. Brain Res. 18:1993;43-58
48. Maggi C.A. The mammalian tachykinin receptors. Gen. Pharmacol. 26:1995;911-944
49. Massi M., Panocka I., de Caro G. The psychopharmacology of tachykinin NK-3 receptors in laboratory animals. Peptides. 21:2000;1597-1609
50. McLean S. Neuropeptide antagonists of the NK1 tachykinin receptor. Med. Res. Rev. 16:1996;297-317
51. McLean S., Ganong A.H., Seeger F.T., Bryce D.K., Pratt J.G., Reynolds L.S., et al. Activity and distribution of different binding sites in brain of non-peptide substance P (NK1) receptor antagonist. Science. 251:1991;437-439
52. Murtra P., Sheasby A.M., Hunt S.P., de Felipe C. Rewarding effects of opiates are absent in mice lacking the receptor for substance P. Nature. 405:2000;180-183
53. Nikolaus S., Huston J.P., Hasenohrl R.U. The neurokinin-1 receptor antagonist WIN51,708 attenuates the anxiolytic-like effects of ventralpallidal substance P injection. NeuroReport. 10:1999;2293-2296
54. Otsuka M., Yoshioka K. Neurotransmitter functions of mammalian tachykinins. Physiol. Rev. 73:1993;229-308
55. Papp M., Vassout A., Gentsch C. The NK-1 receptor antagonist NKP608 has an antidepressant-like effect in the chronic mild stress model of depression in rats. Behav. Brain Res. 115:2000;19-23
56. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods. 14:1985;149-167
57. Ramos A., Mormede P. Stress and emotionality: a multidimensional and genetic approach. Neurosci. Biobehav. Rev. 22:1998;33-57
58. Regoli D., Boudon A., Fauchere J.-L. Receptors and antagonists for substance P and related peptides. Pharmacol. Rev. 46:1994;551-599
59. 3 receptor involvement in anxiety. Neuropeptides. 33:1999;181-188
60. Rodgers R.J. Animal models of 'anxiety': where next? Behav. Pharmacol. 8:1997;477-496
61. Rodgers R.J., Johnson N.J.T. Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Pharmacol. Biochem. Behav. 52:1995;297-303
62. Rodgers R.J., Cao B.-J., Dalvi A., Holmes A. Animal models of anxiety: an ethological perspective. Braz. J. Med. Biol. Res. 30:1997;289-304
63. Rodgers R.J., Haller J., Halasz J., Mikics E. 'One-trial sensitization' to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze. Eur. J. Neurosci. 17:2003;1279-1286
64. Rosen A., Brodin K., Eneroth P., Brodin E. Short-term restraint stress and s.c. saline injection alter tissue levels of substance P and cholecystokinin in the periaqueductal grey and limbic regions of rat brain. Acta Physiol. Scand. 146:1992;341-348
65. 1) receptors attenuates neonatal vocalisation in guinea-pigs and mice. Neuropharmacology. 39:2000;1413-1421
66. 1) receptor in assays for antidepressant and anxiolytic drugs. Behav. Pharmacol. 12:2001;497-508
67. 1) receptor antagonist L-760735 inhibits fear conditioning in gerbils. Neuropharmacology. 44:2003;516-523
68. Santarelli L., Gobbi G., Debs P.C., Sibille E.L., Blier P., Hen R., et al. Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. PNAS. 98:2001;1912-1917
69. 1 receptor in the brain: pharmacology and putative functions. Eur. J. Pharmacol. 375:1999;51-60
70. Snider R.M., Constantine J.W., Lowe J.A., Longo K.P., Lebel W.S., Woody H.A., et al. A potent non-peptide antagonist of the substance P (NK1) receptor. Science. 251:1991;435-437
71. Spooren W.P.J.M., Schoeffter P., Gasparini F., Kuhn R., Gentsch C. Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP and NKP608). Eur. J. Pharmacol. 435:2002;161-170
72. Stout S.C., Owens M.J., Nemeroff C.B. Neurokinin1 receptor antagonists as potential antidepressants. Annu. Rev. Pharmacol. Toxicol. 41:2001;877-906
73. 2 receptor antagonists in the mouse light-dark box. Eur. J. Pharmacol. 250:1993;R11-R12
74. Tattersall F.D., Rycroft W., Francis B., Pearce D., Merchant K., MacLeod A.M., et al. Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology. 35:1996;1121-1129
75. Teixeira R.M., Santos A.R.S., Ribeiro S.J., Calixto J.B., Rae G.A., De Lima T.C.M. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. Eur. J. Pharmacol. 311:1996;7-14
76. Treit D., Menard J., Royan C. Anxiogenic stimuli in the elevated plus-maze. Pharmacol. Biochem. Behav. 33:1993;463-469
77. Uys J.D.K., Stein D.J., Daniels W.M.U., Harvey B.H. Animal models of anxiety disorders. Curr. Psychiat. Rep. 5:2003;274-281
78. Varty G.B., Cohen-Williams M.E., Morgan C.A., Pylak U., Duffy R.A., Lachowicz J.E., et al. The gerbil elevated plus-maze II: anxiolytic-like effects of selective neurokinin NK1 receptor antagonists. Neuropsychopharmacology. 27:2002;371-379
79. 1 receptor antagonist: behavioural effects. Neuropeptides. 26(Suppl):1994;S38
80. Vassout A., Veenstra S., Hauser K., Ofner S., Brugger F., Schilling W., et al. NKP608: a selective NK-1 receptor antagonist with anxiolytic-like effects in the social interaction and social exploration test in rats. Regul. Peptides. 96:2000;7-16
81. Vendruscola L.F., Takahashi R.N., Bruske G.R., Ramos A. Evaluation of the anxiolytic-like effect of NKP608, an NK1-receptor antagonist, in two inbred rat strains that display genetically-determined differences in anxiety-related behaviors. Psychopharmacology. 169:2003;287-293
82. 2 receptor antagonist, in rodent and primate models of anxiety. Psychopharmacology. 121:1995;186-191
83. Weiss SM. Pharmacological and behavioural examination of the defensive reactions of laboratory mice to the calls of the Tawny Owl. PhD thesis, University of Leeds; 1995.
84. Westenberg H.G.M. Facing the challenge of social anxiety disorder. Eur. Neuropsychopharmacol. 9(Suppl. 3):1999;S93-S99